...goal of achieving $20 billion in revenue and a gross margin of around 50% to 2030, a shift from its previous target of 2025-2027.
AstraZeneca #ZEG (NASDAQ:AZN) ADRs rose 0.5% after UBS upgraded its recommendation for the pharmaceutical giant’s stock to "neutral" from "sell”, following a 24%...